Anti Glaucoma Agents
Anti Glaucoma Agents
Bimatosoft Eye Drops
Composition – Bimatoprost 0.03% w/v
Indications – Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension in adults (as monotherapy or as adjunctive therapy to beta-blockers).
- Bimatoprost 0.03% is an efficacious treatment modality for patients in reduction of IOP.
- Lowers pressure in the eye by increasing the amount of fluid that drains from the eye.
- Potent tool in the treatment of Normal Tension Glaucoma in patients with an IOP of 18 mmHg or less.
Presentation- Vial of 3 ml
Close
Brimonid Eye Drops
Composition- Brimonidine Tartrate 0.2 % w/v, Stabilized Oxychloro Complex 0.005% w/v
Indications– Glaucoma, Ocular Hypertension
- Effectively reduced IOP whether used as monotherapy, replacement therapy, or adjunctive therapy.
- Used safely and reliably to reduce IOP in glaucoma and OHT, and it may also reduce the risk of glaucomatous progression independent of its effects on IOP.
Presentation- Vial of 5 ml
Close
Brimotim Eye Drops
Composition– Brimonidine Tartrate 0.2 % w/v, Timolol Maleate 0.5% w/v
Indications– Glaucoma, Ocular Hypertension
- Provided greater IOP-lowering efficacy than either 0.5% timolol twice daily or 0.2% brimonidine 3 times daily used as monotherapy.
- An efficacious & safe therapy with alpha-agonist & beta blocker.
Presentation- Vial of 5 ml
Close
Gludrop Eye Drops
Composition– Timolol Maleate 0.5 w/v
Indications– Open Angle Glaucoma, Ocular Hypertension, Normal Tension Glaucoma
- First line therapy in elevated IOP (Intra Ocular Pressure).
- Timolol monotherapy offers lower cost of care over 5 years compared to prostaglandin analogues.
Presentation- Vial of 5 ml
Close
Travosoft Eye Drops
Composition – Travoprost IP 0.04 mg
Indications – Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
- Low rates of topical and systemic adverse reactions, strong ocular hypotensive efficacy, and once-a-day dosing make travoprost a first-line treatment for patients affected with elevated IOP.
- Exerts its ocular hypotensive action mainly by increasing uveoscleral outflow, but some effects on trabecular meshwork may be present as well
- Provides sustained IOP reduction throughout the 24-hour dosing interval in subjects with ocular hypertension or open-angle glaucoma.
- Superior to timolol in lowering IOP in patients with POAG (Primary Open Angle Glaucoma)
Presentation- Vial of 3 ml
Close
